Pfizer/Pharmacia Merger Review: Firms Expect Second-Request From FTC
Executive Summary
The Federal Trade Commission review of the Pfizer/Pharmacia merger should progress relatively smoothly because the same FTC reviewers worked with Pfizer on the Warner-Lambert deal, CEO Hank McKinnell told the Bear Stearns healthcare conference in New York City Sept. 17
You may also be interested in...
Pfizer’s Friendly Tack: McKinnell Shares Credit With Hassan, Offers No. 2 Spot
Pfizer's $60 bil. offer for Pharmacia could be a landmark event in the remaking of the Pfizer image, as well as a large-scale strategic move to broaden Pfizer's product line into new specialties and deepen the pipeline
Pfizer/Warner Pro Forma Accounting Shows 1.5% Margin Benefit From Lipitor
Pfizer/Warner-Lambert's pro forma operating margins will be 1.5 percentage points closer to the Pfizer level after the elimination of double-counting of Lipitor sales.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011